Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules

• Natalia Sutiman,

  Affiliation Clinical Pharmacology, Singapore Health Services, Singapore, Singapore

  ⨯
• Zhenxian Zhang,

  Affiliation Clinical Pharmacology, Singapore Health Services, Singapore, Singapore

  ⨯
• Eng Huat Tan,

  Affiliation Division of Medical Oncology, National Cancer Center, Singapore, Singapore

  ⨯
• Mei Kim Ang,

  Affiliation Division of Medical Oncology, National Cancer Center, Singapore, Singapore

  ⨯
• Shao-Weng Daniel Tan,

  Affiliation Division of Medical Oncology, National Cancer Center, Singapore, Singapore

  ⨯
• Chee Keong Toh,

  Affiliation Division of Medical Oncology, National Cancer Center, Singapore, Singapore

  ⨯
• Quan Sing Ng,

  Affiliation Division of Medical Oncology, National Cancer Center, Singapore, Singapore

  ⨯
• Balram Chowbay,

  Affiliations Clinical Pharmacology, Singapore Health Services, Singapore, Singapore, Division of Medical Sciences, National Cancer Center, Singapore, Singapore, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore

  ⨯
• Wan-Teck Lim

  * E-mail: darren.lim.w.t@singhealth.com.sg

  Affiliations Division of Medical Oncology, National Cancer Center, Singapore, Singapore, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore, Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore

  ⨯